Is Roche A Buy At $45?

Is Roche A Buy At $45?

The stock price gain over the past two years can primarily be attributed to strong revenue and earnings growth for the company.. The company's newer drugs have far been able to more than offset the decline seen from the old drugs.. While Pharmaceuticals sales were largely driven by higher contribution from the company's new drugs, Diagnostics segment sales were driven by strong uptick in molecular testing, as emergency and COVID-19 testing increased.. The company also guided for low-mid single-digit revenue and earnings growth for the full year.. Our analysis on ' Roche's Revenues ', provides more details on the company's business model, segments, historical revenues, and our forecasts.. From a longer term point of view, new drugs remain the key growth driver for Roche .. Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you touch, read, or hear about everyday, impact its stock price.. The platform uses extensive data to show in a single snapshot what drives the value of a company's business..